Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 29, 2024 07:00 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer
May 28, 2024 07:00 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Therapeutics Announces Board Chair Transition
May 20, 2024 16:00 ET
|
Nurix Therapeutics, Inc.
David L. Lacey steps down from chair role and will remain board member and retain committee leadership roles Current board member Julia P. Gregory unanimously elected new board chair SAN FRANCISCO,...
Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
May 14, 2024 10:00 ET
|
Nurix Therapeutics, Inc.
Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer time on therapy in CLL patients including patients with...
Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
May 07, 2024 07:00 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 16, 2024 18:21 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at...
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
April 11, 2024 23:38 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public offering of 10,166,667 shares of its common...
Nurix Therapeutics Announces Proposed Public Offering
April 11, 2024 16:00 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
April 10, 2024 07:00 ET
|
Nurix Therapeutics, Inc.
Extended the Strategic Collaboration with Gilead Sciences Extended the Strategic Collaboration with Sanofi to Develop Novel Orally Available Targeted Protein Degrader of STAT6 Presented new case...
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
April 09, 2024 13:15 ET
|
Nurix Therapeutics, Inc.
Presented new case studies demonstrating clinical responses in two patients with B cell malignancies, chronic lymphocytic leukemia (CLL) and primary central nervous system lymphoma (PCNSL), each with...